Efficient derivation and inducible differentiation of expandable skeletal myogenic cells from human ES and patient-specific iPS cells

Nature Protocols

Volumn 10, Issue 7, 2015, Pages 941-958

  Maffioletti, Sara M ^a   Gerli, Mattia F M ^a   Ragazzi, Martina ^a   Dastidar, Sumitava ^b   Benedetti, Sara ^a,d   Loperfido, Mariana ^b,c   Vandendriessche, Thierry ^b,c   Chuah, Marinee K ^b,c   Tedesco, Francesco Saverio ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MYOD1 PROTEIN; MYOD PROTEIN; MYOD1 MYOGENIC DIFFERENTIATION PROTEIN;

ARTICLE; CELL DENSITY; CELL DIFFERENTIATION; CELL ISOLATION; CELL SPECIFICITY; CELL SURFACE; CONTROLLED STUDY; EMBRYOID BODY; EMBRYONIC STEM CELL; GENE; GENE THERAPY; HUMAN; HUMAN CELL; MESOANGIOBLAST; MULTINUCLEAR CELL; MUSCULAR DYSTROPHY; MYOD1 GENE; MYOTUBE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SKELETAL MYOGENIC CELL; STEM CELL; STEM CELL CULTURE; STEM CELL TRANSPLANTATION; ANIMAL; CELL CULTURE; CRYOPRESERVATION; CYTOLOGY; GENE EXPRESSION; GENETICS; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MOUSE; MUSCLE DEVELOPMENT; SKELETAL MYOBLAST;

IPS; MUS;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; CRYOPRESERVATION; EMBRYONIC STEM CELLS; GENE EXPRESSION; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE; MUSCLE DEVELOPMENT; MYOBLASTS, SKELETAL; MYOD PROTEIN;

EID: 84933048269     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2015.057     Document Type: Article

References (52)

1. Mercuri, E. & Muntoni, F. Muscular dystrophies. Lancet 381, 845-860 (2013).
2. Benedetti, S., Hoshiya, H. & Tedesco, F.S. Repair or replace? Exploiting novel gene and cell therapy strategies for muscular dystrophies. FEBS J. 280, 4263-4280 (2013).
3. Fairclough, R.J., Perkins, K.J. & Davies, K.E. Pharmacologically targeting the primary defect and downstream pathology in Duchenne muscular dystrophy. Curr. Gene Ther. 12, 206-244 (2012).
4. Perie, S. et al. Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a phase I/IIa clinical study. Mol. Ther. 22, 219-225 (2014).
5. Dellavalle, A. et al. Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nat. Cell Biol. 9, 255-267 (2007).
6. Sacco, A. et al. Short telomeres and stem cell exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell 143, 1059-1071 (2010).
7. Blau, H.M., Webster, C. & Pavlath, G.K. Defective myoblasts identifed in Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. USA 80, 4856-4860 (1983).
8. Cohn, R.D. et al. Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell 110, 639-648 (2002).
9. Kudryashova, E., Kramerova, I. & Spencer, M.J. Satellite cell senescence underlies myopathy in a mouse model of limb-girdle muscular dystrophy 2H. J. Clin. Invest. 122, 1764-1776 (2012).
10. Cassano, M. et al. α-sarcoglycan is required for FGF-dependent myogenic progenitor cell proliferation in vitro and in vivo. Development 138, 4523-4533 (2011).
11. Tedesco, F.S. et al. Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy. Sci. Transl. Med. 4, 140ra189 (2012).
12. Yamanaka, S. Induced pluripotent stem cells: past, present, and future. Cell Stem Cell 10, 678-684 (2012).
13. Gerli, M.F., Maffoletti, S.M., Millet, Q. & Tedesco, F.S. Transplantation of induced pluripotent stem cell-derived mesoangioblast-like myogenic progenitors in mouse models of muscle regeneration. J. Vis. Exp. e50532 (2014).
14. Li, O. et al. Human iPSC-derived mesoangioblasts, like their tissue-derived counterparts, suppress T cell proliferation through IDO-and PGE-2-dependent pathways. F1000 Res. 2, 24 (2013).
15. Goldberg-Cohen, I., Beck, G., Ziskind, A. & Itskovitz-Eldor, J. Vascular cells. Methods Enzymol. 418, 252-266 (2006).
16. Dey, J. et al. MyoD is a tumor suppressor gene in medulloblastoma. Cancer Res. 73, 6828-6837 (2013).
17. Rideout, W.M. III et al. Progressive increases in the methylation status and heterochromatinization of the myoD CpG island during oncogenic transformation. Mol. Cell. Biol. 14, 6143-6152 (1994).
18. Ferreira, L.M. & Mostajo-Radji, M.A. How induced pluripotent stem cells are redefning personalized medicine. Gene 520, 1-6 (2013).
19. Barberi, T. et al. Derivation of engraftable skeletal myoblasts from human embryonic stem cells. Nat. Med. 13, 642-648 (2007).
20. Darabi, R. et al. Human ES-and iPS-derived myogenic progenitors restore DYSTROPHIN and improve contractility upon transplantation in dystrophic mice. Cell Stem Cell 10, 610-619 (2012).
21. Awaya, T. et al. Selective development of myogenic mesenchymal cells from human embryonic and induced pluripotent stem cells. PLoS ONE 7, e51638 (2012).
22. Goudenege, S. et al. Myoblasts derived from normal hESCs and dystrophic hiPSCs effciently fuse with existing muscle fbers following transplantation. Mol. Ther. 20, 2153-2167 (2012).
23. Tanaka, A. et al. Effcient and reproducible myogenic differentiation from human iPS cells: prospects for modeling Miyoshi myopathy. PLoS ONE 8, e61540 (2013).
24. Abujarour, R. et al. Myogenic differentiation of muscular dystrophy-specifc induced pluripotent stem cells for use in drug discovery. Stem Cells Transl. Med. 3, 149-160 (2014).
25. + skeletal muscle precursors from human pluripotent stem cells. Stem Cell Rep. 1, 620-631 (2013).
26. Xu, C. et al. A zebrafsh embryo culture system defnes factors that promote vertebrate myogenesis across species. Cell 155, 909-921 (2013).
27. Shelton, M. et al. Derivation and expansion of PAX7-positive muscle progenitors from human and mouse embryonic stem cells. Stem Cell Reports 3, 516-529 (2014).
28. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fbroblasts by defned factors. Cell 131, 861-872 (2007).
29. Afatoonian, B. et al. Generation of Sheffeld (Shef) human embryonic stem cell lines using a microdrop culture system. In vitro Cell. Dev. Biol. Anim. 46, 236-241 (2010).
30. Watanabe, K. et al. A ROCK inhibitor permits survival of dissociated human embryonic stem cells. Nat. Biotechnol. 25, 681-686 (2007).
31. Sanes, J.R. The basement membrane/basal lamina of skeletal muscle. J. Biol. Chem. 278, 12601-12604 (2003).
32. Malinda, K.M. Matrigel migration and angiogenesis assay. Methods Mol. Biol. 467, 287-294 (2009).
33. Ponce, M.L. Tube formation: an in vitro Matrigel angiogenesis assay. Methods Mol. Biol. 467, 183-188 (2009).
34. Grefte, S., Vullinghs, S., Kuijpers-Jagtman, A.M., Torensma, R. & Von den Hoff, J.W. Matrigel, but not collagen I, maintains the differentiation capacity of muscle derived cells. Biomed. Mater. 7, 055004 (2012).
35. Kuhl, U., Timpl, R. & von der Mark, K. Synthesis of type IV collagen and laminin in cultures of skeletal muscle cells and their assembly on the surface of myotubes. Dev. Biol. 93, 344-354 (1982).
36. Yin, H., Price, F. & Rudnicki, M.A. Satellite cells and the muscle stem cell niche. Physiol. Rev. 93, 23-67 (2013).
37. Tonlorenzi, R., Dellavalle, A., Schnapp, E., Cossu, G. & Sampaolesi, M. Isolation and characterization of mesoangioblasts from mouse, dog, and human tissues. Curr. Protoc. Stem Cell Biol. chapter 2 Unit 2B1 (2007).
38. Tedesco, F.S. et al. Stem cell-mediated transfer of a human artifcial chromosome ameliorates muscular dystrophy. Sci. Transl. Med. 3, 96ra78 (2011).
39. Kimura, E. et al. Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy. Hum. Mol. Genet. 17, 2507-2517 (2008).
40. Dorchies, O.M. et al. The anticancer drug tamoxifen counteracts the pathology in a mouse model of Duchenne muscular dystrophy. Am. J. Pathol. 182, 485-504 (2013).
41. Nakano-Okuno, M., Borah, B.R. & Nakano, I. Ethics of iPSC-based clinical research for age-related macular degeneration: patient-centered risk-beneft analysis. Stem Cell Rev. 10, 743-752 (2014).
42. Cyranoski, D. Japanese woman is frst recipient of next-generation stem cells. Nature doi:10.1038/nature.2014.15915 (12 September 2014).
43. Bejjani, B.A. & Shaffer, L.G. Application of array-based comparative genomic hybridization to clinical diagnostics. J. Mol. Diagn. 8, 528-533 (2006).
44. Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 102, 1555-1577 (2010).
45. Montini, E. et al. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest. 119, 964-975 (2009).
46. Aiuti, A. et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151 (2013).
47. Biff, A. et al. Lentiviral hematopoietic stem cell gene therapy benefts metachromatic leukodystrophy. Science 341, 1233158 (2013).
48. Matrai, J. et al. Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specifc tolerance in mice with low genotoxic risk. Hepatology 53, 1696-1707 (2011).
49. Matrai, J., Chuah, M.K. & VandenDriessche, T. Recent advances in lentiviral vector development and applications. Mol. Ther. 18, 477-490 (2010).
50. Oshimura, M., Uno, N., Kazuki, Y., Katoh, M. & Inoue, T. A pathway from chromosome transfer to engineering resulting in human and mouse artifcial chromosomes for a variety of applications to bio-medical challenges. Chromosome Res. 23, 111-133 (2015).
51. Tedesco, F.S. Human artifcial chromosomes for Duchenne muscular dystrophy and beyond: challenges and hopes. Chromosome Res. 23, 135-141 (2015).
52. Follenzi, A. & Naldini, L. Generation of HIV-1-derived lentiviral vectors. Methods Enzymol. 346, 454-465 (2002).